View in EDS

Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
Authors: Zhang QY; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China., Ding W; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China., Mo JS; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China., Ou-Yang SM; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China., Lin ZY; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China., Peng KR; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China., Liu GP; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China., Lu JJ; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China., Yue PB; Department of Medicine, Division of Hematology-Oncology, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA., Lei JP; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China., Wang YD; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China. wangydsyj@163.com., Zhang XL; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. zhangxlei5@mail.sysu.edu.cn.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2024 Aug; Vol. 45 (8), pp. 1701-1714. Date of Electronic Publication: 2024 Apr 12.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38609562
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+QY%22">Zhang QY</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.<br /><searchLink fieldCode="AU" term="%22Ding+W%22">Ding W</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.<br /><searchLink fieldCode="AU" term="%22Mo+JS%22">Mo JS</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.<br /><searchLink fieldCode="AU" term="%22Ou-Yang+SM%22">Ou-Yang SM</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.<br /><searchLink fieldCode="AU" term="%22Lin+ZY%22">Lin ZY</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.<br /><searchLink fieldCode="AU" term="%22Peng+KR%22">Peng KR</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.<br /><searchLink fieldCode="AU" term="%22Liu+GP%22">Liu GP</searchLink>; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China.<br /><searchLink fieldCode="AU" term="%22Lu+JJ%22">Lu JJ</searchLink>; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.<br /><searchLink fieldCode="AU" term="%22Yue+PB%22">Yue PB</searchLink>; Department of Medicine, Division of Hematology-Oncology, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.<br /><searchLink fieldCode="AU" term="%22Lei+JP%22">Lei JP</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.<br /><searchLink fieldCode="AU" term="%22Wang+YD%22">Wang YD</searchLink>; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China. wangydsyj@163.com.<br /><searchLink fieldCode="AU" term="%22Zhang+XL%22">Zhang XL</searchLink>; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. zhangxlei5@mail.sysu.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100956087%22">Acta pharmacologica Sinica</searchLink> [Acta Pharmacol Sin] 2024 Aug; Vol. 45 (8), pp. 1701-1714. <i>Date of Electronic Publication: </i>2024 Apr 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100956087 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1745-7254 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216714083%22">16714083 </searchLink><i>NLM ISO Abbreviation: </i>Acta Pharmacol Sin <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38609562
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41401-024-01261-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1701
    Titles:
      – TitleFull: Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang QY
      – PersonEntity:
          Name:
            NameFull: Ding W
      – PersonEntity:
          Name:
            NameFull: Mo JS
      – PersonEntity:
          Name:
            NameFull: Ou-Yang SM
      – PersonEntity:
          Name:
            NameFull: Lin ZY
      – PersonEntity:
          Name:
            NameFull: Peng KR
      – PersonEntity:
          Name:
            NameFull: Liu GP
      – PersonEntity:
          Name:
            NameFull: Lu JJ
      – PersonEntity:
          Name:
            NameFull: Yue PB
      – PersonEntity:
          Name:
            NameFull: Lei JP
      – PersonEntity:
          Name:
            NameFull: Wang YD
      – PersonEntity:
          Name:
            NameFull: Zhang XL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2024 Aug
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1745-7254
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Acta pharmacologica Sinica
              Type: main
ResultId 1